Regenicin, Inc.
RGIN · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $95 | $0 | $0 | $0 |
| G&A Expenses | $233 | $268 | $146 | $153 |
| SG&A Expenses | $233 | $268 | $146 | $153 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $328 | $268 | $146 | $153 |
| Operating Income | -$328 | -$268 | -$146 | -$153 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$9 | -$10 | -$9 | -$10 |
| Pre-Tax Income | -$336 | -$278 | -$155 | -$163 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$336 | -$278 | -$190 | -$164 |
| % Margin | – | – | – | – |
| EPS | -0.002 | -0.002 | -0.001 | -0.001 |
| % Growth | -21.1% | -58.3% | -9.1% | – |
| EPS Diluted | -0.002 | -0.002 | -0.001 | -0.001 |
| Weighted Avg Shares Out | 153,483 | 153,483 | 153,483 | 153,483 |
| Weighted Avg Shares Out Dil | 153,483 | 153,483 | 153,483 | 153,483 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $9 | $9 | $9 | $9 |
| Depreciation & Amortization | $1 | $55 | $20 | $86 |
| EBITDA | -$327 | -$213 | -$126 | -$153 |
| % Margin | – | – | – | – |